Methylation and intratumoural heterogeneity of 14-3-3 σ in oral cancer

Oncology Reports

Volumn 18, Issue 4, 2007, Pages 817-824

  Bhawal, Ujjal Kumar ^a,b   Tsukinoki, Keiichi ^a   Sasahira, Tomonori ^b   Sato, Fuyuki ^c   Mori, Yusuke ^a   Muto, Noriko ^a   Sugiyama, Masaru ^d   Kuniyasu, Hiroki ^b  

^a KANAGAWA DENTAL COLLEGE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

14 3 3 ; CyclinD1; Heterogeneity; Methylation; Oral squamous cell carcinoma

Indexed keywords

AZACITIDINE; CYCLIN D; CYCLINE; ENZYME INHIBITOR; EXONUCLEASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; SFN PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; DNA METHYLATION; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GINGIVA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUTH TUMOR; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CYCLINS; DNA METHYLATION; ENZYME INHIBITORS; EXONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GINGIVA; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NEOPLASM PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38449084403     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.4.817     Document Type: Article

References (34)

1. Rosenquist M, Sehnke P, Ferl RJ, Sommarin M and Larsson C: Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity? J Mol Evol 51: 446-458, 2000.
2. Wang W and Shakes DC: Molecular evolution of the 14-3-3 protein family. J Mol Evol 43: 384-398, 1996. (Pubitemid 26337547)
3. Leffers H, Madsen P, Rasmussen HH, Honore B, Andersen AH, Walbum E, Vandekerckhove J and Celis JE: Molecular cloning and expression of the transformation sensitive epithelial marker stratifin: a member of a protein family that has been involved in the protein kinase C signalling pathway. J Mol Biol 231: 982-998, 1993. (Pubitemid 23209874)
4. Prasad GL, Valverius EM, McDuffie E and Cooper HL: Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 3: 507-513, 1992.
5. Vellucci VF, Germino FJ and Reiss M: Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. Gene 166: 213-220, 1995. (Pubitemid 26008831)
6. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997. (Pubitemid 127376388)
7. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
8. Dellambra E, Patrone M, Sparatore B, Negri A, Ceciliani F, Bondanza S, Molina F, Cancedda FD and De Luca M: Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. J Cell Sci 108: 3569-3579, 1995.
9. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T and Imai K: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
10. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M and Takahashi T: Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers. Oncogene 21: 2418-2424, 2002. (Pubitemid 34407301)
11. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5 CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000. (Pubitemid 32103610)
12. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20: 3348-3353, 2001. (Pubitemid 32588983)
13. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000. (Pubitemid 30367521)
14. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ and Crook T: Coincident inactivation of 14-3-3 sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 21: 1876-1881, 2002. (Pubitemid 34259190)
15. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, Tavassoli M, Gusterson B and Crook T: Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16 (INK4a) silencing and human papillomavirus negativity. Cancer Res 62: 2072-2076, 2002. (Pubitemid 34408454)
16. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO and Goggins M: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162: 1151-1162, 2003. (Pubitemid 36350660)
17. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C and Goggins M: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63: 4158-4166, 2003. (Pubitemid 36917941)
18. Bhatia K, Siraj AK, Hussain A, Bu R and Gutierrez MI: The tumor suppressor gene 14-3-3 sigma is commonly methylated in normal and malignant lymphoid cells. Cancer Epidemiol Biomarkers Prev 12: 165-169, 2003. (Pubitemid 36194008)
19. Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994. (Pubitemid 24363801)
20. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
21. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571, 1993. (Pubitemid 23234349)
22. Dhar S, Squire JA, Hande MP, Wellinger RJ and Pandita TK: Inactivation of influences telomere behavior and ionizing radiation-induced chromosomal instability. Mol Cell Biol 20: 7764-7772, 2000.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
24. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S and Brambilla C: Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5: 243-250, 1999. (Pubitemid 29085175)
25. Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T and Yamamoto K: The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4152-4157, 1999. (Pubitemid 30013799)
26. Catteau A, Harris WH, Xu CF and Solomon E: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18: 1957-1965, 1999. (Pubitemid 29150082)
27. Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T and Ushijima T: Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 32: 79-84, 2002. (Pubitemid 41288919)
28. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthan J, Tretiakova M, Das S and Olopade OI: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65: 10692-10699, 2005. (Pubitemid 41713336)
29. Fu H, Subramanian RR and Masters SC: 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40: 617-647, 2000. (Pubitemid 30340695)
30. Muslin AJ and Xing H: 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal 12: 703-709, 2000. (Pubitemid 32056337)
31. Tzivion G, Shen YH and Zhu J: 14-3-3 proteins: bringing new definitions to scaffolding. Oncogene 20: 6331-6338, 2001. (Pubitemid 32977842)
32. van Hemert MJ, Steensma HY and van Heusden GP: 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 23: 936-946, 2001.
33. Laronga C, Yang HY, Neal C and Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275: 23106-23112, 2000. (Pubitemid 30646202)
34. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, Okamura K and Yaegashi N: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10: 2687-2693, 2004. (Pubitemid 38509143)